Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1967
Name leiomyosarcoma
Definition A smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer muscle cancer smooth muscle cancer leiomyosarcoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Dasatinib leiomyosarcoma not applicable detail...
Unknown unknown Dactolisib leiomyosarcoma not applicable detail...
Unknown unknown Aldoxorubicin + Dactolisib leiomyosarcoma not applicable detail...
Unknown unknown Aldoxorubicin + Buparlisib leiomyosarcoma not applicable detail...
Unknown unknown Pazopanib leiomyosarcoma not applicable detail...
Unknown unknown Anlotinib leiomyosarcoma not applicable detail...
FGFR1 positive PD173074 leiomyosarcoma decreased response detail...
FGFR1 positive AZD4547 leiomyosarcoma decreased response detail...
FGFR1 positive Infigratinib leiomyosarcoma decreased response detail...
Unknown unknown Alisertib leiomyosarcoma not applicable detail...
Unknown unknown LY3039478 leiomyosarcoma not applicable detail...
Unknown unknown Regorafenib leiomyosarcoma not applicable detail...
Unknown unknown Pembrolizumab leiomyosarcoma no benefit detail...
Unknown unknown Trabectedin leiomyosarcoma not applicable detail...
Unknown unknown Doxorubicin + Nilotinib leiomyosarcoma not applicable detail...
Unknown unknown Ganetespib + Sirolimus leiomyosarcoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00356031 Phase II Bevacizumab Bevacizumab and Radiation Therapy for Sarcomas Completed
NCT01446809 Phase I Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + Pazopanib Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Completed
NCT01498484 Phase II EB-VST cells Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies Completed
NCT02301039 Phase II Pembrolizumab A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas Active, not recruiting
NCT02303262 Phase II Gemcitabine + Mocetinostat A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma Completed
NCT02584309 Phase II Dexrazoxane Doxorubicin + Olaratumab Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting
NCT02601209 Phase Ib/II Pazopanib Sapanisertib Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Active, not recruiting
NCT02815995 Phase II Durvalumab + Tremelimumab Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes Active, not recruiting
NCT02923778 Phase II Talimogene laherparepvec Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery Recruiting
NCT02987959 Phase II Sapanisertib Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas Active, not recruiting
NCT03009201 Phase I Doxorubicin + Ribociclib Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery Active, not recruiting
NCT03016819 Phase III Anlotinib Dacarbazine A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma (APROMISS) Recruiting
NCT03074318 Phase Ib/II Avelumab + Trabectedin Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery Active, not recruiting
NCT03114527 Phase II Everolimus + Ribociclib Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) Recruiting
NCT03282344 Phase II Nivolumab + NKTR-214 A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma Active, not recruiting
NCT03437070 Phase I Doxorubicin + Olaratumab + Trabectedin Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma Withdrawn
NCT03670069 Phase I Itacitinib Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas Recruiting
NCT03718091 Phase II Berzosertib M6620 (VX-970) in Selected Solid Tumors Recruiting
NCT03719430 Phase II APX005M + Doxorubicin + Olaratumab APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma Recruiting
NCT03761095 Phase I Dacarbazine + PTC596 A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) Recruiting
NCT03851614 Phase II Cediranib + Durvalumab Durvalumab + Olaparib Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) Recruiting
NCT03860207 Phase Ib/II Hu3F8-BsAb Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers Recruiting
NCT03899805 Phase II Eribulin + Pembrolizumab A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas Recruiting
NCT04028063 Phase II Balstilimab + Doxorubicin + Zalifrelimab Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas Recruiting
NCT04076579 Phase II Olaparib + Trabectedin Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma Recruiting
NCT04200443 Phase II Cabozantinib + Temozolomide Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma Recruiting
NCT04242238 Phase I Avelumab + DCC-3014 Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas Recruiting
NCT04420975 Phase I BO-112 + Nivolumab Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma Not yet recruiting